Your session is about to expire
← Back to Search
Monoclonal Antibodies
Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration
Phase 4
Waitlist Available
Led By John Galic, MD
Research Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group
Drug Has Already Been Approved
Pivotal Trial
Summary
The purpose of the investigators study is to look at the visual outcomes of Ranibizumab injections in combination with photodynamic therapy for the treatment of neovascular age-related macular degeneration.
Eligible Conditions
- Age-Related Macular Degeneration
- Visual Acuity
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
3Treatment groups
Active Control
Group I: Pre-PDTActive Control1 Intervention
Participants in this group will receive an intraocular Ranibizumab injection one week prior to the first PDT with verteporfin.
Group II: No PDTActive Control1 Intervention
Participants in this group will receive an intraocular Ranibizumab injection with no accompanying PDT with verteporfin.
Group III: Post-PDTActive Control1 Intervention
Participants in this group will receive an intraocular Ranibizumab injection one week post the first PDT with verteporfin.
Find a Location
Who is running the clinical trial?
McGill University Health Centre/Research Institute of the McGill University Health CentreLead Sponsor
471 Previous Clinical Trials
166,827 Total Patients Enrolled
John Galic, MDPrincipal InvestigatorMontreal Retina Institute
John Chen, MDPrincipal InvestigatorMontreal Retina Institute